DNA ends SGEN anti-CD40 antibody deal

Seattle Genetics (SGEN) said Genentech (DNA) ended a 1999 licensing deal to develop SGEN's SGN-14 anti- CD40 monoclonal antibody. As terminated, SGEN may independently develop the antibody and DNA wil...